ESR1 and breast cancer: These findings are consistent with previous studies on the effects of disease-specific PRS on the first breast cancers in BRCA1 and BRCA2 heterozygotes20,24 and with the higher relative prevalence of ER-negative and ER-positive contralateral breast cancers respectively, in this cohort.